CRP is synthesized by the liver in response to several inflammatory cytokines and is a well-established biomarker of inflammation and infection. Elevated CRP levels are associated with several diseases, including inflammatory bowel disease, rheumatoid arthritis, cardiovascular disease, infection, and cancer. SYnAbs Monoclonal antibodies offer several advantages for CRP diagnosis in a precision medicine context.
How epigenetic alterations on histones are strong biomarkers of disease evolution and how to target these post-translational modifications effectively with SYnAbs higher specific mouse and rat monoclonal antibodies
Thanks to unique technologies to break immune tolerance, SYnAbs generate monoclonal antibodies to Matrix metalloproteinases (MMPs), extracellular proteinase enzymes involved in the degradation of the extracellular matrix.
SYnAbs and Domain Therapeutics enter into a strategic partnership for the discovery and development of therapeutic antibodies targeting complex G Protein Coupled Receptor targets for immuno-oncology indications